🟢 Icecure Medical is trading 12.35% up in pre-market after first two U.S. patients enrolled in ChoICE

Icecure Medical is trading at $1.18, up +12.35% in pre-market after the company announced October 20 that the first two patients enrolled at U.S. sites in its ChoICE study.

• The study evaluates ProSense cryoablation for low-risk breast cancer.
• It plans to enroll approximately 400 patients across up to 30 U.S. sites.
• No volume data was provided.